moneyheap
ROIV · Analysis updated Nov 10, 2026, 6:00 PM ET
Why is Roivant Sciences Ltd. Common Shares (ROIV) stock moving?
ROIV closed at $41.19 on Nov 10, up about 15% from $35.89 on Nov 2 and near the 30-day high of $41.43 set on Nov 9. The rally came on heavy volume: Nov 4 (11.7M), Nov 6 (12.3M), Nov 9 (12.2M, earnings day) and Nov 10 (10.6M), well above the 4-7M range of late October. Fundamentally, Q2 results beat on both EPS ($(0.27) vs $(0.34) estimate) and sales, with LISRAYA generating $31.0M in net product revenue in its first five weeks on the market. The company also held $4.2B in cash and marketable securities at Sept 30 and repurchased about 2.1M shares for roughly $72.5M in the quarter. HC Wainwright maintained its Buy and raised its target to $48, and Citigroup had already raised its target to $56 on Oct 28. Negatives include the 300mg IMVT-1402 dose showing no difference from placebo in rheumatoid arthritis, Immunovant signaling it is unlikely to advance the drug in Sjögren's beyond Phase 2, and a $7.26M insider sale by Eric Venker on Nov 6. The brepocitinib sNDA for non-infectious uveitis is planned for H1 2027, which provides a forward catalyst after the positive CLARITY Phase 3 readouts. The main uncertainty is whether the earnings-driven rally holds after a roughly 15% move in seven sessions.
News behind the analysis
- HC Wainwright & Co. Maintains Buy on Roivant Sciences, Raises Price Target to $48HC Wainwright kept its Buy rating and raised its price target to $48 from the prior level. The stock closed at $41.19 on Nov 10.
- Roivant Reports Financial Results for the Second Quarter Ended September 30, 2026 and Provides Business UpdateRoivant reported Q2 results, highlighting early revenue from LISRAYA and progress across its clinical pipeline. The results were filed in an 8-K on Nov 9.
- Roivant Sciences Q2 EPS $(0.27) Beats $(0.34) Estimate, Sales $35.121M Beat $4.109M EstimateQ2 loss per share was $(0.27) against a $(0.34) estimate, and reported sales were $35.121M against a $4.109M estimate. The sales comparison looks inconsistent with the other reported figures and should be checked.
- Roivant Q2 Lisraya Net Product Revenue $31.0M In First 5 Weeks Of LaunchLISRAYA generated $31.0M in net product revenue in its first five weeks on the market. This is the first commercial sales data point for the product.
- Roivant Repurchased 2.1M Shares For ~$72.5M In Q2Roivant bought back about 2.1M shares for roughly $72.5M during the quarter. The buyback supports the share count and signals management confidence in the stock.
- Roivant Cash, Equivalents & Marketable Securities $4.2B At Sept 30Cash, cash equivalents and marketable securities totaled $4.2B at Sept 30, giving the company a large liquidity cushion for its pipeline and launch.
- Immunovant's IMVT-1402 600mg Meets Primary Endpoint In Difficult-To-Treat Rheumatoid Arthritis Trial; 300mg Dose Shows No Difference From PlaceboThe 600mg dose of IMVT-1402 met its primary endpoint in a difficult-to-treat rheumatoid arthritis trial, while the 300mg dose showed no difference from placebo. The mixed dose result limits the read-through to the program.
- Immunovant Unlikely To Advance IMVT-1402 In Sjögren's Disease Beyond Ongoing Phase 2Immunovant indicated that IMVT-1402 is unlikely to advance in Sjögren's disease beyond the ongoing Phase 2 study. This narrows the pipeline's near-term opportunities.
- Roivant Plans sNDA For Brepocitinib In Non-Infectious Uveitis In H1 2027Roivant plans to file a supplemental NDA for brepocitinib in non-infectious uveitis in the first half of 2027, following positive Phase 3 CLARITY results. The filing is a forward milestone rather than a current catalyst.
- Roivant Sciences Insider Sold Shares Worth $7,262,000Eric Venker, President of Roivant and CEO of Immunovant, sold 200,000 shares worth about $7.26M, according to an SEC filing. Insider selling is a modest negative signal.
About Roivant Sciences Ltd. Common Shares
Roivant Sciences is a Bermuda-incorporated biopharmaceutical company that develops and sells medicines through a group of specialized subsidiaries it calls "Vants," such as Priovant, Immunovant and Pulmovant. In August 2026 it won FDA approval for its first internally developed drug in this new phase, LISRAYA (brepocitinib), for dermatomyositis, and it holds a large cash pile of roughly $4 billion that it uses for new drug licensing deals and share buybacks.
How it makes money
Product revenue is still small (only a few million dollars a year recently) and is just beginning with the launch of LISRAYA for dermatomyositis. Roivant has mostly paid for its work with cash from past deals, such as selling subsidiaries and drug rights (for example, selling Telavant to Roche), along with interest on its cash reserves. It may also receive future milestone payments, royalties or settlements from licensing and patent litigation, such as its lipid-nanoparticle patent cases against Moderna and Pfizer/BioNTech. It is not yet consistently profitable.
What usually moves ROIV
- LISRAYA (brepocitinib) launch sales
- Clinical trial readouts (uveitis, IMVT-1402, mosliciguat)
- FDA regulatory decisions
- New in-licensing deals and capital allocation
- LNP patent litigation outcomes